September is Prostate Cancer Awareness Month – Scientists across ORIEN and Aster Insights are working together, armed with Avatar clinicogenomic data, to unlock the complexities of this disease and improve outcomes for men needing novel therapeutic options. @gdgrass

Longitudinal clinical data w/hundreds of data elements + rich molecular data custom built for oncology discovery + digital pathology images w/AI-powered insights = an unmatched research solution for discovery & clinical development. #OncologyResearch #RWD

Scientists across #ORIEN are continually innovating & studying a broad range of topics such as tumor microbiomes, #immuno-oncology, inherited risks, #HealthEquity, #DataScience, #Sarcoma, #BreastCancer, #GI, Thyroid #cancers, and more.

We collaborate with experts at the nation's top cancer centers to study real-world patient data retrospectively & prospectively. These unique pan-cancer insights accelerate oncology discovery & development and advance cancer care. #CancerResearch #RWD

On #WorldLungCancerDay, we're proud to be a part of the early development & indication expansion of pembrolizumab, a revolutionary treatment option for many types of cancer, incl. advanced #NSCLC. Our partnerships w/industry, academic cancer centers & patients make this possible.

RT @CRC_AACR: #ICYMI: The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint i….

RT @ATarhiniMDPhD: Our latest published article |#Melanoma #tumor #microbiome & #TME #immunogenicity, response & resistance to #immunecheck….

RT @OhioStateMedOnc: 📝New publication from @dspakowicz & the exORIEN Consortium: The tumor #microbiome as a predictor of outcomes in patien….

Industry partners often remark on the depth & quality of Aster data + our unique approach to collaborative research with #ORIEN cancer centers across the U.S. Learn from Dr. Eric Rubin how our solutions informed the early development strategy of Keytruda

Excited to host Dr. @KimrynRathmell, NCI Director, as our keynote speaker & Dr. Richard Pazdur, Director, @FDAOncology Center of Excellence, for a fireside chat at our 5th annual #ORIEN Scientific Summit this fall! #CollaborativeScience #OncologyResearch

New #CancerResearch from our #ORIEN Genitourinary RIG led by Dr. Sumati Gupta, characterizes inherited urothelial cancer risk & emphasizes the significance of comprehensive germline testing in patients w/non-bladder primary disease sites. #UrothelialCancer

Uncover new targets & biomarkers, accelerate clinical trials & more, w/the deepest multimodal dataset for #OncologyResearch & development. • Longitudinal lifetime-consented clinical data .• Tumor & Germline DNA .• Tumor RNA .• Digital pathology .

Happy Independence Day!

RT @NCICancerCtrl: The @theNCI Division of Cancer Control & Population Sciences welcomes Dr. Erin Siegel as the new Associate Director of o….

RT @ATarhiniMDPhD: Excited to share our latest published article | Differences in Co-Expression of #TCell #CoInhibitory & #CoStimulatory Mo….

In June, we recognize the strength and resilience of cancer survivors. We celebrate life, spread hope, and continue our commitment to #CancerResearch to improve outcomes for all. Learn from survivors Barney Morris and Deb Collyar why they advocate for patients & cancer research.

RT @MoffittNews: Ahmad Tarhini, MD, PhD (@ATarhiniMDPhD) presented on how immune cell state atlas can predict the benefits of ICIs in #mela….

RT @UKMarkey: GYN oncology fellow, @TaylorARives, MD found there are genomic differences in #EndometrialCancer of non-Appalachian & Appalac….

Today at #ASCO24, Dr. Taylor Rives, @UKMarkey, presents collaborative #ORIEN research about molecular differences in Kentucky Appalachian populations which may reveal opportunities for treatment and reduce #cancer disparities. More: #CollaborativeScience

RT @RoswellPark: Chief Fellow ⁦@patel_riya7⁩ proudly sharing her research with Dr. Renuka Iyer at #ASCO24. Using ORIEN data, they uncovered….